Precigen Financials

PGEN Stock  USD 1.78  0.02  1.11%   
Based on the analysis of Precigen's profitability, liquidity, and operating efficiency, Precigen may be sliding down financialy. It has an above-average odds of going through some form of financial crisis next quarter. At this time, Precigen's Other Current Liabilities is very stable compared to the past year. As of the 18th of March 2025, Total Stockholder Equity is likely to grow to about 241.2 M, while Total Assets are likely to drop about 129.1 M. Key indicators impacting Precigen's financial strength include:
Current ValueLast YearChange From Last Year 10 Year Trend
Current Ratio3.713.44
Significantly Up
Very volatile
The essential information of the day-to-day investment outlook for Precigen includes many different criteria found on its balance sheet. An individual investor should monitor Precigen's cash flow, debt, and profitability to accurately make informed decisions on whether to invest in Precigen.

Net Income

(90.63 Million)

  

Precigen Stock Summary

Precigen competes with CorMedix, Sangamo Therapeutics, Aptose Biosciences, Corvus Pharmaceuticals, and Immutep. Precigen, Inc. discovers and develops the next generation of gene and cellular therapies in the United States. Precigen, Inc. was founded in 1998 and is based in Germantown, Maryland. Precigen operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 456 people.
Specialization
Health Care, Pharmaceuticals, Biotechnology & Life Sciences
InstrumentUSA Stock View All
ExchangeNASDAQ Exchange
ISINUS74017N1054
CUSIP46122T102 74017N105
LocationMaryland; U.S.A
Business Address20358 Seneca Meadows
SectorBiotechnology
IndustryHealth Care
BenchmarkDow Jones Industrial
Websiteprecigen.com
Phone301 556 9900
CurrencyUSD - US Dollar

Precigen Key Financial Ratios

Precigen Key Balance Sheet Accounts

202020212022202320242025 (projected)
Total Assets314.6M359.9M216.0M151.0M135.9M129.1M
Other Current Liab31.7M28.6M30.1M19.5M22.5M30.4M
Net Debt130.5M151.3M46.6M(481K)(553.2K)(525.5K)
Retained Earnings(1.8B)(1.9B)(1.9B)(2.0B)(1.8B)(1.7B)
Accounts Payable4.6M3.1M4.1M1.7M2.0M1.9M
Cash51.8M42.9M4.9M7.6M6.8M6.5M
Net Receivables20.4M2.0M13.8M1.6M1.4M1.3M
Other Current Assets17.0M45.7M48.1M4.3M5.0M4.7M
Total Liab247.4M252.5M89.7M32.5M29.3M27.8M
Total Current Assets148.9M156.6M118.2M68.8M79.1M75.1M
Short Term Debt3.0M1.4M44.4M1.2M1.4M1.3M
Intangible Assets65.4M54.1M44.5M40.7M36.6M34.8M
Inventory16.1M11.4M13.3M287K0.90.86
Good Will54.4M54.1M36.9M26.6M24.0M22.8M
Net Tangible Assets(60.4M)(52.6M)(915K)126.3M113.6M81.8M
Long Term Debt211.2M186.3M171.5M182.7M210.2M107.7M
Long Term Debt Total211.2M186.3M171.5M182.7M210.2M107.7M
Capital Surpluse1.8B1.9B2.0B2.0B2.3B1.7B

Precigen Key Income Statement Accounts

202020212022202320242025 (projected)
Interest Expense18.4M18.9M6.8M468K538.2K511.3K
Total Revenue103.2M103.9M26.9M6.2M7.2M6.8M
Gross Profit47.7M45.5M20.6M106K121.9K115.8K
Operating Income(85.7M)(78.8M)(74.6M)(88.9M)(80.0M)(84.0M)
Ebit(85.5M)(92.2M)(73.2M)(95.9M)(86.3M)(90.6M)
Research Development41.6M50.1M47.2M48.6M43.8M82.4M
Ebitda(70.4M)(84.1M)(66.0M)(89.2M)(80.3M)(84.3M)
Income Before Tax(103.9M)(96.9M)(80.0M)(96.4M)(86.7M)(91.1M)
Net Income(103.8M)(96.8M)(79.8M)(95.9M)(86.3M)(90.6M)
Income Tax Expense(82K)(160K)(189K)(458K)(526.7K)(553.0K)
Cost Of Revenue55.5M58.4M6.3M6.1M5.5M5.2M
Tax Provision(82K)(160K)(189K)(458K)(526.7K)(553.0K)
Interest Income2.5M1.6M133K3.2M2.9M2.8M
Net Interest Income(15.9M)(17.3M)(6.6M)2.8M2.5M2.6M
Non Recurring120.5M23.0M543K1.1M1.0M957.6K

Precigen Key Cash Accounts

202020212022202320242025 (projected)
Change To Inventory4.1M2.5M(1.9M)2.3M2.7M2.8M
Change In Cash(16.2M)(8.9M)5.3M(40.7M)(36.7M)(34.8M)
Free Cash Flow(84.5M)(63.0M)(70.0M)(68.5M)(61.6M)(64.7M)
Depreciation17.5M13.8M10.8M6.7M7.7M7.3M
Other Non Cash Items78.4M9.7M(91.5M)9.0M10.3M9.8M
Capital Expenditures7.5M7.2M4.9M1.5M1.8M1.7M
Net Income(170.5M)(92.2M)28.3M(95.9M)(86.3M)(90.6M)
End Period Cash Flow52.3M43.3M48.6M7.8M9.0M8.6M
Investments(35.4M)(74.1M)68.4M(3.1M)(2.8M)(2.6M)
Change Receivables49K4.3M(6.6M)(13.5M)(12.2M)(11.6M)
Net Borrowings1.2M(2.4M)(466K)(155.3M)(139.8M)(132.8M)
Change To Netincome149.6M47.9M11.7M10.8M9.7M9.3M

Precigen Financial Ratios Relationships

Comparative valuation techniques use various fundamental indicators to help in determining Precigen's current stock value. Our valuation model uses many indicators to compare Precigen value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Precigen competition to find correlations between indicators driving Precigen's intrinsic value. More Info.
Precigen is rated below average in return on equity category among its peers. It is rated below average in return on asset category among its peers . At this time, Precigen's Return On Equity is very stable compared to the past year. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Precigen's earnings, one of the primary drivers of an investment's value.

Precigen Systematic Risk

Precigen's systematic risk plays a vital role in portfolio allocation when considering its stock to be added to a well-diversified portfolio. Precigen volatility which cannot be eliminated through diversification, requires returns over the risk-free rate. Over the long run, a well-diversified portfolio provides returns that match its exposure to systematic risk. In this case, investors face a trade-off between expected returns and systematic risk and, therefore, can only reduce a portfolio's exposure to systematic risk by sacrificing expected returns on the portfolio.
The output start index for this execution was five with a total number of output elements of fifty-six. The Beta measures systematic risk based on how returns on Precigen correlated with the market. If Beta is less than 0 Precigen generally moves in the opposite direction as compared to the market. If Precigen Beta is about zero movement of price series is uncorrelated with the movement of the benchmark. if Beta is between zero and one Precigen is generally moves in the same direction as, but less than the movement of the market. For Beta = 1 movement of Precigen is generally in the same direction as the market. If Beta > 1 Precigen moves generally in the same direction as, but more than the movement of the benchmark.
Today, most investors in Precigen Stock are looking for potential investment opportunities by analyzing not only static indicators but also various Precigen's growth ratios. Consistent increases or decreases in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's growth growth rates may not be enough to decide which company is a better investment. That's why investors frequently use static breakdown of Precigen growth as a starting point in their analysis.

Price Earnings To Growth Ratio

0.99

At this time, Precigen's Price Earnings To Growth Ratio is very stable compared to the past year.

Precigen March 18, 2025 Opportunity Range

Along with financial statement analysis, the daily predictive indicators of Precigen help investors to analyze its daily demand and supply, volume, patterns, and price swings to determine the real value of Precigen. We use our internally-developed statistical techniques to arrive at the intrinsic value of Precigen based on widely used predictive technical indicators. In general, we focus on analyzing Precigen Stock price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build Precigen's daily price indicators and compare them against related drivers.
When determining whether Precigen offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Precigen's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Precigen Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Precigen Stock:
Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Precigen. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in income.
To learn how to invest in Precigen Stock, please use our How to Invest in Precigen guide.
You can also try the Portfolio Center module to all portfolio management and optimization tools to improve performance of your portfolios.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Precigen. If investors know Precigen will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Precigen listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(0.54)
Revenue Per Share
0.015
Quarterly Revenue Growth
(0.31)
Return On Assets
(0.43)
Return On Equity
(1.37)
The market value of Precigen is measured differently than its book value, which is the value of Precigen that is recorded on the company's balance sheet. Investors also form their own opinion of Precigen's value that differs from its market value or its book value, called intrinsic value, which is Precigen's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Precigen's market value can be influenced by many factors that don't directly affect Precigen's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Precigen's value and its price as these two are different measures arrived at by different means. Investors typically determine if Precigen is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Precigen's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.